Flibanserin is under clinical development by Sprout2 and currently in Phase II for Male Hypoactive Sexual Desire Disorder. According to GlobalData, Phase II drugs for Male Hypoactive Sexual Desire Disorder does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Flibanserin LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Flibanserin overview

Flibanserin (Addyi) is phenylpiperazines derivative acts as an gynecological agent. It is formulated as film coated tablets for oral route of administration. Addyi is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual  desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty.

It is under development for the treatment of hypoactive sexual desire disorder in males.

Sprout2 overview

Sprout2, develops compound to treat hypoactive sexual desire disorder. The company is headquartered in Raleigh, North Carolina, the US.

For a complete picture of Flibanserin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.